Kornimate/medical-research-clean huggingface dataset:
fertility limiting diseases of pelvic organs and their influence on receptivity of endometrial cavity: prospective clinical trial

Conditions: Adenomyosis; Fibroid Uterus; Endometriosis

Summary: in this project, we will characterize the effects of fertility limiting diseases of pelvic organs on the receptivity of the endometrium. the primary aim of the project is the characterization of endometrium in patients with infertility suffering from ad, uf and de, and compare it with infertile patients with minimal or mild endometriosis but no ad or uf (etrs group), and with healthy women with only male factor of infertility (ctrl group, controls). the proper infertility treatment of patients with ad,uf and endometriosis is controversial and lacking clear evidence based algorithms. despite their topical character, especially ad and de (and ufs as well if present as multiple lesions) can be classified as systemic diseases in relation to women´s fertility. the presumed impact of these pathologies to endometrial receptivity (no matter they do not occur in the uterine cavity itself) can beseen as a fascinating hypothesis. eradication of these diseases could have a potential to increase the prognosis of these women fundamentally.

the project will be studied in two parts - laboratory and clinical. in the laboratory part, the parameters of endometrial receptivity will be specified in women with uf, ad, de, minimal and mild endometriosis and in healthy controls. these parameters will be also compared in surgically treated patients before and after the procedures. this data will also be compared with patients from both control groups (etrs, ctrl). first, we will perform bulk rna sequencing (rna-seq), to characterize the main differences in rna expression of the endometrium between women with successful and unsuccessful conceptions. the candidate genes will be used for choosing the rtqpcr controlled set of samples for single-nucleus rna-seq (snrna-seq) profiling of the endometrial tissue. the results will be validated using rt-qpcr. in the clinical part, we will analyse the reproductive results of surgical and conservative management of infertility associated with ad and uf. collectively, our data will provide information for the development of new diagnostic tools for better investigation and choice of treatment for patients with infertility. this project is not a clinical trial.

Eligibility criteria:
inclusion criteria: * agreement with participation in the study * age between 18 - 45 years (at the start of patient´s participation in the study)women with at least 1 year infertility exclusion criteria: -

Keywords: adenomyosis cytoreductive resection myomectomy endometriosis endometrial receptivity
efficacy study of phytotherapy "raylis" in congestive processes of the pelvic organs (prostatostasis)

Conditions: Congestive Processes Of The Pelvic Organs (Prostatostasis); Erectile Dysfunction; Sexual Function

Summary: the purpose of this study is to investigate the efficacy of phytotherapy "raylis" (ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) in congestive processes of the pelvic organs (prostatostasis) in congestive processes of the pelvic organs (prostatostasis)


Eligibility criteria:
inclusion criteria: * age 20-60 years * symptoms of prostatostasis lasting for at least 3 months during the past 6 months: * pathological changes on uroflowmetry (maximum flow rate of less than 15 ml / s, average urinary flow rate of less than 12 ml / sec) * trus prostate volume more than 22 ml at trus * trus picture of prostatostasis * i-pss 7-20 * iief-5) - 12-21 exclusion criteria: * contraindications and limitations to use of the drug raylis listed in the instructions for medical use \* * diabetes mellitus (type 1 and type 2, decompensation) * neurogenic disorders (acute cerebral circulatory disorders, alzheimer's disease, spinal cord injury) * a history of pelvic trauma * patients who had undergone radical prostatectomy and other surgical interventions on the pelvic organs * concomitant use of supplements to improve the erectile function, use of the anti-androgens, anti-depressants, finasteride. * diagnosed bph * current participation in a clinical trial and / or study medication for 30 days prior to inclusion * any form of substance abuse, mental disorder or condition which, in the opinion of the investigator, may complicate communication with the researcher. * the inability or unwillingness to comply with the scheme of visits according to protocol.

Keywords: ginseng prostatostasis erectile dysfunction
[study evaluating the efficacy and safety of a digital therapeutic as an adjunct to tau in postpartum depression]

Conditions: Postpartum Depression

Summary: this study evaluates the efficacy of two digital therapeutics, wb001 and ed001, on depressive symptoms among women diagnosed with postpartum depression.

this randomized, double-blind, controlled trial evaluates the efficacy and safety of 8 weeks of treatment of two digital therapeutics in a population of women with mild to moderate postpartum depression. patients will be referred by an obstetrician, pediatrician, or other healthcare professional, or by other digital and site based recruitment methods and, if interested, will complete the pre-screening process. those confirmed as eligible will be scheduled to attend a screening/baseline onsite visit. eligible participants will be randomized to one of the two groups and will receive instructions on downloading and using the smartphone application to which they were randomized. participants will use the app as instructed and will attend telehealth visits to complete assessments for the primary and safety endpoints at weeks 4 and 8 (eot).

Eligibility criteria:
inclusion criteria: 1. must have primary residence in the united states 2. must be ≤ 92 days postpartum 3. must be women aged 22-45 years who had onset of a major depressive episode any time during pregnancy or within 4 weeks following delivery 4. must own or have regular access to a smartphone (android or ios smartphone with a recent, supported operating system), and has reliable wi-fi access or sufficient data plan to engage with assigned treatment condition for the duration of the study 5. participants must have current mild-moderate depression as measured by the hamd-6 score \>7 and \<13 at screening 6. participant must have a form of tau, defined as clinician supervised outpatient care management and includes follow-up visits, medication, psychotherapy, or some combination thereof 7. tau must be regularly scheduled or stable for at least 4 weeks prior to baseline (bl) visit exclusion criteria: 1. gestation less than 28 weeks 2. hamd-6 score ≤7 or ≥13 (severe depression) at screening 3. currently pregnant or plans to become pregnant within the next 8 weeks 4. history of drug and/or alcohol use disorder within the past 12 months 5. lifetime history of suicide attempt or ideation with a plan and intent to harm oneself during the current episode of ppd 6. current or lifetime psychosis 7. current or lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, and/or homicidal or infanticidal ideation 8. history of antidepressant treatment with ketamine/esketamine, electroconvulsive therapy, vagal nerve stimulation, or a deep brain stimulation device 9. history of treatment-resistant depression (trd) 10. fetal demise within the past 18 months

Keywords: postpartum depression ppd postpartum depression treatment ppd treatment smartphone application digital therapeutic
intravenous lidocaine versus morphine for severe pain in the ed

Conditions: Pain

Summary: objective: evaluate the analgesic efficacy of intravenous (iv) lidocaine versus provider chosen dose of iv morphine for the treatment of severe pain in the emergency department. study design: open-label, randomized controlled pilot study.

objective: the purpose of this pilot study is to determine the analgesic efficacy of intravenous lidocaine versus morphine for the treatment of severe pain in the emergency department (ed). study design: open-label, randomized, controlled pilot trial. participants: investigators and research assistants will recruit patients ≥18 years old with severe pain (nrs ≥7) and an anticipated stay in the emergency department ≥1 hour. a sample size calculation was performed and 32 patients will be enrolled. intervention: after a trained research assistant obtains written informed consent, eligible participants will be randomized to the intravenous lidocaine or morphine arms of the study. in the intravenous lidocaine arm, patients will receive iv lidocaine (75 mg if \ 100 kg) over 10 minutes in a 100 ml normal saline minibag followed by a 50 minute iv lidocaine drip (75 mg if \ 100 kg). in the morphine arm, the ed provider will choose an appropriate dose of morphine for the patient. at 20 and 40 minutes, the participants will be asked "would you like additional pain medication?". participants responding in the affirmative will receive morphine 4 mg iv. data collection: the trained research assistant will collect data on the patients' pain scores, side effects, and rescue morphine. statistical analysis: investigators will perform descriptive statistics and compare pain scores and pain relief at each time point with unpaired t-tests.

Eligibility criteria:
inclusion criteria: * subject has severe pain (nrs ≥7) * subject has anticipated ed stay of ≥1 hour exclusion criteria: * high acuity trauma patients * patients deemed to critically ill by ed provider * active psychosis * pregnancy * history of heart block or bradycardia * allergy to lidocaine or amide type local anesthetic * history of seizures
histopathological evaluation of product of conception in sporadic and recurrent abortions

Conditions: Recurrent Abortion

Summary: 1. to evaluate histopathological findings of products of conception in both sporadic and recurrent miscarriage. 2. to determine the prevalence of chronic histiocytic intervillositis in both sporadic and recurrent miscarriage.

early miscarriage is a term used to describe the loss of pregnancy within the first 12 weeks of gestation .this diagnosis concerns 10-15% of all pregnancies and is made based on additional tests such as serial determinations of chorionic gonadotropin concentration and imaging examinations ultrasonography. depending on the clinical presentation and results of ultrasonography, miscarriages can be divided into complete spontaneous miscarriage, and incomplete miscarriage, when the width of the echo of residual tissues in the uterine cavity exceeds 10 mm on ultrasonography and is accompanied by the presence of clinical symptoms such as vaginal bleeding and abdominal pain .the other type of miscarriage is defined as retained products of conception (rpoc) and refers to the state when the gestational sac contains the embryo with crown-rump length (crl) of \> 7 mm but embryonic cardiac activity is invisible. empty gestational sac is diagnosed when the gestational sac with a diameter of \> 25 mm and without an embryo is visible in the uterine cavity on ultrasonography . histopathological examination of products of conception is an integral and a routine component of the management of patients with early pregnancy failure . two important primary reasons for such an examination are to confirm the presence of an intrauterine gestation and to exclude gestational trophoblastic disease in the form of partial or complete hydatidiform mole .

Eligibility criteria:
inclusion criteria: * all pregnants with clinical symptoms and signs of abortion * fit for medical induction of abortion * fit for surgical procedure exclusion criteria: * threatened abortion * complete abortion * unfit participants for medical abortion * unfit participants for surgical procedure
clinical usefulness and quality of life of oros hydromorphone in patients who have not been treated with a strong opioid

Conditions: Pain

Summary: the primary purpose of this study is to evaluate the usefulness of hydromorphone to treat cancer pain in patients who have not been treated with a strong opioid.

this is a multicenter, prospective, open-label (all people know the identity of the intervention) and observational study. patients selected for the proposed study are patients complaining of cancer pain who visit or are hospitalized at the research centers during the study, who are not being treated with strong continuous opioid (narcotic medication used against the pain), and who require cancer pain control with hydromorphone, at the investigator's discretion. the study will evaluate the changes in pain relief, level of sleep deprivation, and the patients' quality of life before and after administration of hydromorphone.

Eligibility criteria:
inclusion criteria: - patients who complain of cancer pain and who require administration of hydromorphone hcl - patients who can follow the requirements of the overall study, including completion of filling out the european organization for research and treatment of cancer quality of life questionnaire, at the investigator's discretion - signed informed consent exclusion criteria: - patients who received strong continuous narcotic analgesics (eg morphine, fentanyl, oxycodone, hydromorphone) within 4 weeks prior to administration of the study drug - patients who have a medical history of receiving drugs in the past or currently, or of drug abuse - patients who did not agree to conduct the approved methods for contraception during the study - patients who have sustained injuries in physical functions or diseases which may cause abnormalities in absorbing the study drug, excessive accumulation and metabolic or elimination disorder - patients who are receiving monoamine oxidase inhibitors (mao) inhibitors or who are within 2 weeks from discontinuation - patients who need to be excluded based on precautions in the user manual of the study drug, notice and contradictions, at the investigator's discretion

Keywords: pain cancer pain hydromorphone hydromorphone oros narcotic analgesics opioid-naive
interest of additional arthroscopic portals in diagnosis of hidden lesions of the medial meniscus in pediatrics knees with acl deficiency

Conditions: Chronic Knee Instability

Summary: peroperatively observative study in pediatric orthopedic center in lyon, france. 50 pediatric patients included in this study, to improve the diagnosis of hidden lesions of the medial meniscus associated with lesions of the anterior cruciate ligament. all the patients need a reconstruction of the acl because of chronic knee instability. all the patients underwent a multi portal arthroscopy during the acl reconstruction : anteromedial and anterolateral and after intercondylar and posteromedial. the study consists in a peroperatively arthroscopic look, in order to diagnose lesions of the posterior horn of the medial meniscus which could be missed in mri and anteromedial and anterolateral arthroscopy. statistics of this lesions are used to study prevalence and diagnosis capacity of this procedures. first, the surgeon did a classic knee arthroscopy. secondarily, he did an intercondylar portal and after a posteromedial portal.


Eligibility criteria:
inclusion criteria: - chronic knee instability with indicated surgery reconstruction exclusion criteria: * pregnancy * no preoperatively knee mri * posteromedial or intercondylar portal failure * social security system membership failure * refusal of consent of child or parents

Keywords: acl hidden lesions of the medial meniscus chronic knee instability intercondylar and posteromedial arthroscopy arthroscopic posteromedial and intercondylar portal diagnosis capacity of hidden lesions of the medial meniscus
a single dose study to test two pediatric forms of ritlecitinib compared with adult ritlecitinib in healthy adults

Conditions: Healthy Participants

Summary: a phase i, single dose study to test two forms of pediatric ritlecitinib compared to adult ritlecitinib in healthy adults aged 18-55 years old. approximately 12 adults will participate for approximately 2.5 months.


Eligibility criteria:
inclusion criteria: * male and female participants who are healthy as determined by medical evaluation including a detailed medical history, complete (full) physical examination, which includes bp and pulse rate measurement, clinical laboratory tests, and 12-lead ecg. * bmi of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy). * known immunodeficiency disorder, including positive serology for hiv at screening, or a first degree relative with a hereditary immunodeficiency * infection with hepatitis b or hepatitis c viruses. * history of any lymphoproliferative disorder * known present or a history of malignancy other than a successfully treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ
comparison of meniscus extrusion between preoperative and postoperative mowhto using ultrasonographic assessment

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to measure the changes in the medial and lateral meniscus extrusion of the knee joint before and after surgery using ultrasound in patients who undergo medial opening wedge high tibial osteotomy, and examine the differences.

high tibial osteotomy (hto) is an established treatment method for medial compartment osteoarthritis with varus knee deformity in a relatively young patient group. excellent outcomes of hto have been reported. however, about 10-30% of patients are not satisfied with the results after surgery. after proximal tibial osteotomy, studies on the factors of dissatisfaction have been actively conducted, but studies on the medial and lateral meniscus extrusion, which can be the cause, are insufficient. the relationship between the prolapse of the medial meniscus and articular cartilage is already well known and is known as an important factor in the progression of arthritis. as such, the association between the knee joint with meniscus extrusion and the general knee joint has been studied, but the effect on the clinical outcome after proximal tibial osteotomy has not been studied. therefore, in this study, the investigators are planning to investigate the differences in clinical outcomes such as the degree and change of medial and lateral meniscus extrusion through non-invasive ultrasound examination before and after surgery in patients who undergo medial open proximal tibial osteotomy. this study will enroll the patients with knee medial compartment osteoarthritis of the knee joint who undergo open proximal tibial osteotomy. the degree of medial and lateral meniscus extrusion will be measured through ultrasound measurements before and after surgery. also, demographic factors and radiographic measurements will be also investigated before and after surgery. in addition, preoperative, postoperative 3, 6, and 1 year clinical results including meniscus extrusion will be compared and judged, and the evaluation will be evaluated by an orthopedic surgeon who has not participated in the operation among registered researchers.

Eligibility criteria:
inclusion criteria: * adults over 20 * medial compartment knee osteoarthritis patients for medial opening wedge high tibial osteotomy * patients who are willing or able to follow doctor's instructions, including joint exercises * patients who have received sufficient explanation for this clinical trial and agreed to participate exclusion criteria: * patients with secondary knee osteoarthritis * patients with inflammatory arthritis or crystalline arthritis * local infection to the lower extremities of the pain area, sepsis, or previous neurological abnormalities. * patients with knee range of motion less than 90 degrees * patients with bmi above 40
evaluation of the contribution of musculoskeletal ultrasound to the general practitioner's overall decision-making strategy

Conditions: Musculoskeletal; Anomaly

Summary: the hypothesis of this study is that musculoskeletal point of care ultrasonography would support the gp's decision and ultimately improve patient management. the aim of this study is to evaluate, in the context of suspected musculoskeletal abnormality, the contribution of musculoskeletal point of care ultrasonography to the general practitioner's overall decision-making strategy, defined according to the following 5 axes: diagnosis (i), therapy (ii), patient orientation (iii), prescription of complementary examinations (iv) and follow-up (v).

the study circuit takes place in a single visit. 1. the investigating physician suspects a musculoskeletal anomaly following an initial clinical examination. 2. the patient (who meets the inclusion criteria and has no non-inclusion criteria) gives consent to participate, after receiving information about the study. 3. the investigator fills in the e-crf (appendix iii), clinical examination, medical interrogation and his or her decisions according to the 5 axes, which cannot be modified, as the structure of the e-crf planned in advance does not allow backtracking. the investigator performs the targeted musculoskeletal ultrasound with his or her personal ultrasound machine, following his or her usual operating procedure. 4. the investigator fills in the e-crf with the results of the targeted ultrasound scan and indicates any modifications to the decision axes.

Eligibility criteria:
inclusion criteria: * person who has received full information on the organization of the research and has given his/her consent * be over 18 years of age * present a symptomatology leading to suspicion of musculoskeletal pathology * be able to give consent * be affiliated to a social security scheme or benefit from such a scheme exclusion criteria: * chronic inflammatory rheumatism (rheumatoid arthritis, spondylitis, psoriatic arthritis, rheumatoid pseudo-polyarthritis, juvenile idiopathic arthritis, lupus, etc.). * subjects benefiting from a legal protection measure (guardianship, curatorship, safeguard of justice). * persons deprived of their liberty by judicial or administrative decision, persons under psychiatric care under articles l3212-1 and l3213-1. * pregnant women * nursing mothers

Keywords: musculoskeletal anomaly ultrasonography general practitioners